Uncovered struts compromise re-endothelization and may induce thrombosis. The new stent approved in China and already used in more than 50,000 patients, is a sirolimus-eluting device with a bio-degradable polymer. Animal studies showed rapid and complete endothelialization. The study included 20 patients with stable angina randomized on a 1:1 ratio to receive, in the same<a href="https://solaci.org/en/2015/06/24/buma-stent-new-sirolimus-eluting-stent-with-bio-degradable-polymer/" title="Read more" >...</a>

Absorbable bioplatforms are considered safe and effective in stable patients but their use in the context of acute myocardial infarction with ST segment elevation has not been reported. Low risk of heart attack with low Killip classification could be the stage for this device. 87 consecutive patients experiencing myocardial infarction with ST elevation underwent primary<a href="https://solaci.org/en/2015/06/24/prague-19-bioabsorbable-platform-for-patients-with-st-segment-elevation/" title="Read more" >...</a>

Late endothelialization of first generation pharmacological stents may predispose thrombosis. Both the drug and the polymer of the platform may affect the rate at which this occurs. This is a prospective, multicenter study which randomized 44 patients with acute coronary syndrome to receive sirolimus-eluting stent with bio-absorbable polymer versus zotarolimus-eluting stent with permanent polymer. The<a href="https://solaci.org/en/2015/06/24/hattrick-oct-biodegradable-polymer-struts-coverage-versus-permanent/" title="Read more" >...</a>

There is still concern about the safety of drug-eluting stents (DES) due to the possibility of late and very late thrombosis. Dual antiplatelet aggregation for a year is recommended for patients receiving DES. The objective of this study was to test the non-inferiority of a new drug-eluting stent in terms of endothelial coverage after 3<a href="https://solaci.org/en/2015/06/24/demonstr8-better-endothelial-coverage-by-oct-for-the-new-des/" title="Read more" >...</a>

We evaluated 41,537 patients admitted with myocardial infarction without ST elevation on the SCAAR register and who had not received IIBIIIB glycoprotein inhibitors and divided them into two groups: 31,351 patients who received heparin versus 10,186 who received bivalirudin. We adjusted baseline characteristics of the two groups using the Propensity score with the exception of<a href="https://solaci.org/en/2015/06/24/scaar-heparin-versus-bivalirudin-in-patients-with-myocardial-infarction-without-st-segment-elevation/" title="Read more" >...</a>

This new stent is a sirolimus-eluting low-profile cobalt chrome platform (80 &micro;m) with a rapid resorption polymer (3 months). Theoretically, it presents less risk of inflammation of the vessel due to the kinetics of drug elution and polymer degradation. The objective of this study was to test the safety and efficacy of the new device.<a href="https://solaci.org/en/2015/06/24/century-new-clinical-results-of-sirolimus-eluting-degradable-polymer-stent/" title="Read more" >...</a>

This study randomized 1:1, &nbsp;906 patients to receive zotarolimus-eluting stent and 905 patients to receive everolimus-eluting stent. The clinical and angiographic characteristics of both groups were similar with approximately 45% of the population experiencing an acute coronary syndrome. There were no significant differences in major cardiac events between the two stents with 6.1% to for<a href="https://solaci.org/en/2015/06/24/dutch-peers-everolimus-des-versus-zotarolimus-des/" title="Read more" >...</a>

From the total of 1900 patients in the FREEDOM study, 1248 did not require insulin (631 received angioplasty and 617 received CABG) and 602 if required (325 received angioplasty and 277 received CABG). Insulin dependent patients were more obese, with higher glycosylated hemoglobin, increased incidence of heart failure and increased incidence of acute coronary syndromes.<a href="https://solaci.org/en/2015/06/24/freedom-insulin-dependent-versus-non-insulin-dependent-with-multivessel-disease/" title="Read more" >...</a>

The ideal therapy for treating in-stent restenosis continues to be debated . The pharmacological balloons showed good results in this context, but no direct comparisons available of pharmacological balloonsversus second-generation DES.This prospective, multicenter randomized 189 patients with in-stent restenosis of conventional stents receiving pharmacological balloon or everolimusDES.The primary endpoint was angiographicat 9 months spotting a<a href="https://solaci.org/en/2015/06/24/ribs-v-pharmacological-balloon-vs-second-generation-drug-eluting-stent-in-the-treatment-of-bms-restenosis/" title="Read more" >...</a>

Few studies have compared head to head the 2nd generation drug eluting stents. This study randomized 1:1 &nbsp;3671 patients to receive a biolimus eluting stent with biodegradable polymer (1880 patients) versus zotarolimus-eluting stent with biocompatible polymer (1791 patients). No significant differences were observed between the two groups in terms of clinical or angiographic features. Approximately<a href="https://solaci.org/en/2015/06/24/sort-out-vi-biolimus-eluting-stent-versus-zotarolimus-eluting-stent-similar-results/" title="Read more" >...</a>